The policy change in Tdap, the tetanus, diphtheria, acellular pertussis vaccine, comes on the heels of pertussis outbreaks across the United States. The new recommendation is to vaccinate pregnant women in each and every pregnancy in the third trimester, preferably between 27 and 36 weeks. This includes pregnant women who have been vaccinated previously. Tdap is FDA approved for adults as single use only, so repeat maternal vaccination is an off-label use. Tdap booster is recommended universally for all adults, including those aged 65 years and older.
There is a change in pneumococcal vaccination strategies for immunocompromised adults. ACIP recommends that pneumococcal conjugate vaccine (PCV) 13 (Prevnar 13), a new PCV vaccine, be given to all immunocompromised adults ages 19 years and older. It should be given in addition to, not instead of, pneumococcal polysaccharide
vaccine (PPSV) 23 (Pneumovax). Patients
include those with functional or anatomic asplenia, HIV infection, cancer, advanced kidney disease, or other immunocompromising conditions. Timing and order of the 2 vaccinations are important, so check the new adult schedule for the details. This recommendation also deviates from FDA licensing. When ACIP made this recommendation, Prevnar was FDA approved for adults age 50 and older but not for those ages 19-49.
Influenza vaccination is recommended for everyone over 6 months old. That still stands, but there has been a name change. Instead of TIV, which stands for trivalent inactivated influenza vaccine, the new name is IIV — inactivated influenza vaccine. Also, starting next year, many manufacturers will transition from a trivalent formulation that covers 2 strains of influenza A and 1 strain of influenza B to a quadrivalent formulation that doubles the coverage for these strains. For specific adult vaccine information at your fingertips, download the ACP Immunization Advisor from the Website or as a mobile app.
Más información: Calendario adultos 2013.CDC